GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Cyclically Adjusted Revenue per Share

Vaxart (Vaxart) Cyclically Adjusted Revenue per Share : $3.81 (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Vaxart Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vaxart's adjusted revenue per share for the three months ended in Dec. 2023 was $0.047. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.81 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -24.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vaxart was 7.60% per year. The lowest was -32.70% per year. And the median was -9.90% per year.

As of today (2024-04-29), Vaxart's current stock price is $0.7097. Vaxart's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $3.81. Vaxart's Cyclically Adjusted PS Ratio of today is 0.19.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vaxart was 1.49. The lowest was 0.02. And the median was 0.42.


Vaxart Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Vaxart's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Cyclically Adjusted Revenue per Share Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.70 8.78 6.52 - 3.81

Vaxart Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.91 5.47 4.84 3.81

Competitive Comparison of Vaxart's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted PS Ratio falls into.



Vaxart Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vaxart's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.047/129.4194*129.4194
=0.047

Current CPI (Dec. 2023) = 129.4194.

Vaxart Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 9.470 99.695 12.294
201406 2.639 100.560 3.396
201409 0.220 100.428 0.284
201412 4.356 99.070 5.690
201503 1.847 99.621 2.399
201506 1.248 100.684 1.604
201509 0.484 100.392 0.624
201512 0.484 99.792 0.628
201603 1.509 100.470 1.944
201606 0.142 101.688 0.181
201609 0.028 101.861 0.036
201612 1.082 101.863 1.375
201703 1.395 102.862 1.755
201706 0.028 103.349 0.035
201709 0.028 104.136 0.035
201712 0.768 104.011 0.956
201803 0.284 105.290 0.349
201806 0.085 106.317 0.103
201809 0.039 106.507 0.047
201812 0.247 105.998 0.302
201903 0.741 107.251 0.894
201906 0.006 108.070 0.007
201909 0.028 108.329 0.033
201912 0.081 108.420 0.097
202003 0.048 108.902 0.057
202006 0.007 108.767 0.008
202009 0.002 109.815 0.002
202012 0.003 109.897 0.004
202103 0.004 111.754 0.005
202106 0.001 114.631 0.001
202109 0.002 115.734 0.002
202112 0.001 117.630 0.001
202203 0.001 121.301 0.001
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.005 127.348 0.005
202306 0.010 128.729 0.010
202309 0.003 129.860 0.003
202312 0.047 129.419 0.047

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Vaxart  (NAS:VXRT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vaxart's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.7097/3.81
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vaxart was 1.49. The lowest was 0.02. And the median was 0.42.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vaxart Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Vaxart's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart (Vaxart) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Executives
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee officer: Chief Financial Officer C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron director 6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg officer: SVP, General Counsel C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid director C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd officer: VP, Corporate Controller, PAO 3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings officer: Chief Medical Officer 1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker officer: Chief Scientific Officer 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour director, officer: President and Chief Executive 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037

Vaxart (Vaxart) Headlines